FDA Approves Theragnostics’ NephroScan Radiodiagnostic Imaging Drug To Detect Kidney Cortical Defects

The U.S. Food and Drug Administration (FDA) approved Theragnostics’ radiodiagnostic imaging drug NephroScan. The drug is used as an aid for evaluating renal parenchymal disorders in adults and children, including term newborn infants. The drug helps detect kidney cortical defects. NephroScan is Theragnostics’ first FDA approved drug.

The drug is manufactured by ROTOP Pharmaka GmbH in Germany. GE Healthcare, a global leader in molecular imaging, serves as the exclusive distributor of the product in the United States and the product is now available for ordering.

Theragnostics is a private clinical-stage pharmaceutical company developing precision oncology products for diagnostic . . .